Released Nov 14, 2024, during market hours
10-Q filed Nov 19, 2024, 50 days after period end · 0001493152-24-046836
Q3 2024 · 10-Q
Revenue$2.26M$2.26M +1.8% vs Q3 2023−6.9% vs Q2 2024
Net Income-$3.55M-$3.55M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.23-$0.23 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$1,355,000+3.7%
Operating Income-$3,744,000N/M
Operating Cash Flowderived-$2,920,000N/M
Free Cash Flowderived-$2,922,000N/M
Margins · derived
Gross margin60.0%+1.1 pt vs Q3 2023
Operating margin-165.9%+19.8 pt vs Q3 2023
Net margin-157.2%+55.1 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $2.26M | $2.22M | $2.07M | $1.67M |
| Net Income | -$3.55M | -$4.71M | -$7.78M | -$9.71M |
| EPS Diluted | -$0.23 | -$0.48 | -$1.00 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aspira Women's Health Inc. · CIK 926617 · Engraved from SEC EDGAR